Niederberger Verena, Eckl-Dorna Julia, Pauli Gabrielle
Dept. of Otorhinolaryngology, Medical University of Vienna, Austria.
Dept. of Otorhinolaryngology, Medical University of Vienna, Austria.
Methods. 2014 Mar 1;66(1):96-105. doi: 10.1016/j.ymeth.2013.07.037. Epub 2013 Aug 3.
Over the last 25 years, recombinant allergens from all important allergen sources have been cloned and are now available as recombinant proteins. These molecules can be produced in practically unlimited amounts without biological or batch-to-batch variability. It has been shown in provocation tests that recombinant allergens have similar clinical effects as their natural counterparts. With the help of these tools it is possible to reveal the precise reactivity profiles of patients and to uncover and differentiate cross-reactivity from genuine sensitization to an allergen source. Although it has been shown some time ago that it would be possible to replace crude allergen extracts with recombinant allergens for skin prick testing, and even though the use of allergen components can improve routine diagnosis, these tools are still not available for clinical routine applications. The use of provocation tests is a crucial step in the development of new, hypoallergenic vaccines for therapy of allergic disease. Here we describe important provocation methods (skin prick test, intradermal test, atopy patch test, nasal provocation, colonoscopic provocation test) and give an overview of the clinical provocation studies which have been performed with recombinant allergens so far.
在过去25年里,来自所有重要过敏原来源的重组变应原已被克隆,现在可作为重组蛋白获得。这些分子可以大量生产,几乎不受生物学因素或批次间差异的影响。激发试验表明,重组变应原与其天然对应物具有相似的临床效果。借助这些工具,可以揭示患者的精确反应谱,并发现和区分交叉反应性与对过敏原来源的真正致敏。尽管早在一段时间前就已表明可以用重组变应原替代粗制变应原提取物进行皮肤点刺试验,而且变应原成分的使用可以改善常规诊断,但这些工具仍未用于临床常规应用。激发试验的使用是开发用于治疗过敏性疾病的新型低变应原性疫苗的关键步骤。在此,我们描述重要的激发方法(皮肤点刺试验、皮内试验、特应性斑贴试验、鼻激发试验、结肠镜激发试验),并概述迄今为止用重组变应原进行的临床激发研究。